Large-scale market evidence now points one way: focused companies tend to outperform diversified conglomerates, and the payoff from slimming a portfolio unfolds over several years, not overnight. A Boston Consulting Group study of 740 companies in the S&P Global 1200 found that focused firms delivered higher relative total shareholder returns than similarly positioned diversified peers, and that companies completing a "focus transformation" saw their average Tobin's Q ratio improve from 1.5x to 1.7x. Johnson & Johnson's dismantling of its century-old diversified model—separating consumer health as Kenvue and moving to concentrate on Innovative Medicine and MedTech—is the highest-profile test of that logic in healthcare. This article explains why markets reward focus, how J&J's shift illustrates the rationale, and how leaders can evaluate their own portfolios.

The Strategic Imperative: Why Focus Outperforms Diversification

Diversification once defined the modern corporation. For more than a century, J&J built its competitive position across pharmaceuticals, medical devices, and consumer health, with distinct revenue streams, shared financial resources, and resilience across market cycles—as Thani Jambulingam notes in Pharmaceutical Executive, that structure helped establish one of the most enduring corporations in healthcare. The logic was stability: weakness in one business could be offset by strength in another.

The case for focus rests on the mirror image of that argument. Concentrated portfolios let leadership direct capital, talent, and management attention toward fewer, higher-potential businesses, and let investors value each business on its own terms rather than through a conglomerate lens. Markets consistently reward strategic clarity and concentrated resource allocation, BCG's researchers conclude from their data. The result is a widening gap in how the two models are priced and how they perform.

Quantitative Evidence: The Market's Preference for Focus

The numbers behind the trend come from BCG's 2025 analysis of market performance, which compared focused and diversified companies across the S&P Global 1200. In one category of companies with similarly stable portfolios, focused companies achieved an average relative total shareholder return of 2.3%, versus 1.6% for diversified ones—a differential the firm attributes to markets rewarding strategic clarity and concentrated resource allocation.

More striking is what happens when diversified companies actively change. BCG identified 172 companies that underwent a "focus transformation" and tracked their performance before and after. The average Tobin's Q ratio—a metric comparing a firm's market value to the replacement cost of its assets—improved from 1.5x to 1.7x after the shift, while companies that moved the other way and diversified saw a decline.

Leaders should note the timeline, however. BCG's analysis indicates that 60% of the total discount reduction is realized within the first year after a portfolio shift, with the remaining 40% materializing over the second and third years, as markets internalize the long-term implications of realignment. A focus transformation is a multi-year value story, not a quick announcement-driven pop.

Johnson & Johnson's Bold Pivot: A Case Study in Strategic Focus

J&J is the concrete illustration of this strategic logic playing out in real time. After decades of a diversified healthcare model, the company announced it would split off its consumer health division—creating Kenvue—within 18 to 24 months, a move it said would unlock "significant value" while allowing it to focus on its faster-growing prescription medicine and medical device businesses, as industry publication pharmaphorum reported. The decision followed similar moves by GlaxoSmithKline and Pfizer, which combined their consumer health units into a joint venture slated for spin-off.

The remaining enterprise is now organized around two segments. In its enterprise business review, the company said it expects MedTech to grow operational sales in the upper range of its markets—projected to grow 5-7% through 2027—and to generate one-third of sales from new products in 2027, while Innovative Medicine is expected to deliver more than 20 novel therapies and more than 50 product expansions by 2030. Its innovation arm describes a MedTech portfolio spanning cardiovascular, orthopaedics, surgery, and vision, aimed at innovations at the intersection of biology and technology.

Yet J&J's shift is not a finished verdict. As Jambulingam observes, the separations of Kenvue and, prospectively, DePuy Synthes test whether Innovative Medicine and MedTech actually create more value together than apart—and patient-level value from new products will depend on real-world evidence. The stated rationale and the observed market trend align, but the specific long-term outcomes for J&J are still unfolding.

Portfolio Strategy Decision Framework

Use the matrix below to evaluate your company's business units against the tests suggested by the evidence: whether units perform better together, how the market prices your structure, and how clearly capital flows to the best opportunities. It is a guide for evaluation, not a single "correct" answer applicable to all companies.

Applying the four tests of corporate ownership to your portfolio
Test The question to answer Evidence signal of a problem What a passing answer looks like
Value Creation (Synergies vs. Dis-synergies) Do our businesses genuinely perform better together than apart, in revenue or cost terms we can name? Synergies are asserted but not demonstrated; shared services cost more than they return, the pattern J&J's separations implicitly challenge. Concrete cross-business advantages—shared technology, channels, or capabilities—evidenced in performance.
Market Performance (Shareholder Return) Is our relative total shareholder return in line with focused peers of similar stability? A persistent gap like the one BCG measured—2.3% average rTSR for focused firms versus 1.6% for diversified firms with similarly stable portfolios—applied to your own comparison set. Relative TSR at or above the focused-peer benchmark, with no persistent conglomerate discount.
Valuation (Tobin's Q) Does the market value our assets above their replacement cost at a level comparable to focused peers? A Tobin's Q below what a "focus transformation" has historically lifted—the BCG cohort moved from 1.5x to 1.7x—suggests the market is applying a diversification discount. Valuation in line with focused peers, or a credible plan to close the gap.
Strategic Clarity & Resource Allocation Does the current structure let capital and management attention flow to the highest-growth segments, the way J&J's post-Kenvue structure concentrates resources on Innovative Medicine and MedTech? High-growth units compete for attention with mature ones; innovation priorities are diffuse across unrelated businesses. Few, clearly prioritized segments with explicit growth and innovation targets, such as the sales-share goals J&J set for new MedTech products.

Interpret your results across all four tests together, not in isolation. Failing the valuation and shareholder-return tests while claiming strong synergies is the classic profile of a portfolio the market does not believe in—the profile that motivated the 172 focus transformations BCG studied. Passing the synergy test convincingly is the strongest argument for keeping a diversified structure, provided the returns and valuation tests confirm it.

Embracing Focus for Future Growth

Business leaders should critically assess their corporate portfolio against market performance data and strategic clarity tests to determine if a shift toward greater focus is warranted. The framework above is corporate-level—it addresses business units, not product lines—and it does not prescribe divestiture in every case; it identifies where the evidence points. Note that this analysis is not investment advice regarding J&J or any other company.

The measurable indicator to watch, whether for your own portfolio or as a benchmark of the trend, is improved Total Shareholder Return and enhanced market valuation (Tobin's Q) relative to peers, alongside clearer capital allocation and innovation priorities. If you do pursue a focus transformation, set expectations to BCG's timeline: only about 60% of the discount reduction arrives in the first year, with the remaining 40% materializing over years two and three. Judge the strategy against that multi-year horizon—and, as J&J's case shows, keep watching whether the remaining businesses actually create more value together than apart.

Sources